1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Opioid Use Disorder Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Buprenorphine
1.2.3 Methadone
1.2.4 Naltrexone
1.3 Market by Application
1.3.1 Global Opioid Use Disorder Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Moderate Pain Treatment
1.3.3 Severe Pain Treatment
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Opioid Use Disorder Market Perspective (2017-2028)
2.2 Opioid Use Disorder Growth Trends by Region
2.2.1 Opioid Use Disorder Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Opioid Use Disorder Historic Market Size by Region (2017-2022)
2.2.3 Opioid Use Disorder Forecasted Market Size by Region (2023-2028)
2.3 Opioid Use Disorder Market Dynamics
2.3.1 Opioid Use Disorder Industry Trends
2.3.2 Opioid Use Disorder Market Drivers
2.3.3 Opioid Use Disorder Market Challenges
2.3.4 Opioid Use Disorder Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Opioid Use Disorder Players by Revenue
3.1.1 Global Top Opioid Use Disorder Players by Revenue (2017-2022)
3.1.2 Global Opioid Use Disorder Revenue Market Share by Players (2017-2022)
3.2 Global Opioid Use Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Opioid Use Disorder Revenue
3.4 Global Opioid Use Disorder Market Concentration Ratio
3.4.1 Global Opioid Use Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Opioid Use Disorder Revenue in 2021
3.5 Opioid Use Disorder Key Players Head office and Area Served
3.6 Key Players Opioid Use Disorder Product Solution and Service
3.7 Date of Enter into Opioid Use Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Opioid Use Disorder Breakdown Data by Type
4.1 Global Opioid Use Disorder Historic Market Size by Type (2017-2022)
4.2 Global Opioid Use Disorder Forecasted Market Size by Type (2023-2028) 5 Opioid Use Disorder Breakdown Data by Application
5.1 Global Opioid Use Disorder Historic Market Size by Application (2017-2022)
5.2 Global Opioid Use Disorder Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Opioid Use Disorder Market Size (2017-2028)
6.2 North America Opioid Use Disorder Market Size by Country (2017-2022)
6.3 North America Opioid Use Disorder Market Size by Country (2023-2028)
6.4 United States
6.5 Canada 7 Europe
7.1 Europe Opioid Use Disorder Market Size (2017-2028)
7.2 Europe Opioid Use Disorder Market Size by Country (2017-2022)
7.3 Europe Opioid Use Disorder Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Opioid Use Disorder Market Size (2017-2028)
8.2 Asia-Pacific Opioid Use Disorder Market Size by Country (2017-2022)
8.3 Asia-Pacific Opioid Use Disorder Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia 9 Latin America
9.1 Latin America Opioid Use Disorder Market Size (2017-2028)
9.2 Latin America Opioid Use Disorder Market Size by Country (2017-2022)
9.3 Latin America Opioid Use Disorder Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Opioid Use Disorder Market Size (2017-2028)
10.2 Middle East & Africa Opioid Use Disorder Market Size by Country (2017-2022)
10.3 Middle East & Africa Opioid Use Disorder Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE 11 Key Players Profiles
11.1 Indivior
11.1.1 Indivior Company Detail
11.1.2 Indivior Business Overview
11.1.3 Indivior Opioid Use Disorder Introduction
11.1.4 Indivior Revenue in Opioid Use Disorder Business (2017-2022)
11.1.5 Indivior Recent Development
11.2 Alkermes
11.2.1 Alkermes Company Detail
11.2.2 Alkermes Business Overview
11.2.3 Alkermes Opioid Use Disorder Introduction
11.2.4 Alkermes Revenue in Opioid Use Disorder Business (2017-2022)
11.2.5 Alkermes Recent Development
11.3 Titan Pharmaceuticals
11.3.1 Titan Pharmaceuticals Company Detail
11.3.2 Titan Pharmaceuticals Business Overview
11.3.3 Titan Pharmaceuticals Opioid Use Disorder Introduction
11.3.4 Titan Pharmaceuticals Revenue in Opioid Use Disorder Business (2017-2022)
11.3.5 Titan Pharmaceuticals Recent Development
11.4 Hikma Pharmaceuticals
11.4.1 Hikma Pharmaceuticals Company Detail
11.4.2 Hikma Pharmaceuticals Business Overview
11.4.3 Hikma Pharmaceuticals Opioid Use Disorder Introduction
11.4.4 Hikma Pharmaceuticals Revenue in Opioid Use Disorder Business (2017-2022)
11.4.5 Hikma Pharmaceuticals Recent Development
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Detail
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Opioid Use Disorder Introduction
11.5.4 Teva Pharmaceuticals Revenue in Opioid Use Disorder Business (2017-2022)
11.5.5 Teva Pharmaceuticals Recent Development
11.6 MediciNova
11.6.1 MediciNova Company Detail
11.6.2 MediciNova Business Overview
11.6.3 MediciNova Opioid Use Disorder Introduction
11.6.4 MediciNova Revenue in Opioid Use Disorder Business (2017-2022)
11.6.5 MediciNova Recent Development
11.7 Orexo
11.7.1 Orexo Company Detail
11.7.2 Orexo Business Overview
11.7.3 Orexo Opioid Use Disorder Introduction
11.7.4 Orexo Revenue in Opioid Use Disorder Business (2017-2022)
11.7.5 Orexo Recent Development
11.8 Camurus
11.8.1 Camurus Company Detail
11.8.2 Camurus Business Overview
11.8.3 Camurus Opioid Use Disorder Introduction
11.8.4 Camurus Revenue in Opioid Use Disorder Business (2017-2022)
11.8.5 Camurus Recent Development
11.9 Omeros
11.9.1 Omeros Company Detail
11.9.2 Omeros Business Overview
11.9.3 Omeros Opioid Use Disorder Introduction
11.9.4 Omeros Revenue in Opioid Use Disorder Business (2017-2022)
11.9.5 Omeros Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
